Farnesyltransferase inhibitors - A novel approach in the treatment of advanced pancreatic carcinomas

Anticancer Research

Volumn 23, Issue 2 A, 2003, Pages 813-818

  Dempke, Wolfram C M ^a  

^a Wilhelm Anton Hospital   (Germany)

Author keywords

Clinical studies; Farnesyltransferase inhibitors; Pancreatic carcinoma; Ras oncogenes

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTINEOPLASTIC AGENT; FLUOROURACIL; GEMCITABINE; L 778123; LONAFARNIB; PROTEIN; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB;

CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG TOLERABILITY; FATIGUE; HUMAN; NAUSEA; NEUTROPENIA; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TOXICITY;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; PANCREATIC NEOPLASMS; PIPERIDINES; PYRIDINES; QUINOLONES; RAS PROTEINS;

EID: 0038538402     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Kelly DM and Benjamin IS: Pancreatic carcinoma. Ann Oncol 6: 19-28, 1995.
2. Wolff RA, Chiao P, Lenzi R, Pisters PWT, Lee JE and Jan NA: Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs 18: 43-56, 2000.
3. Bos JL: Ras oncogenes in human cancers: a review. Cancer Res 49: 4682-4689, 1989.
4. Rowinsky EK, Windle JJ and von Hoff DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17: 3631-3652, 1999.
5. Barbacid M: Ras genes. Ann Rev Biochem 56: 779-827, 1987.
6. Reiss Y, Goldstein JL, Seabra MC, Casely PJ and Brown MS: Inhibition of purified p21 ras farnesyl protein transferase by Cys-AAX tetrapeptides. Cell 62: 81-88, 1990.
7. Adjei AA: Protein farnesyl transferase as a target for the development of anticancer drugs. Drugs Fut 25: 1069-1079, 2000.
8. Ashar HR, James L and Gray K: FTIs block the farnesylation of CENP-E and CENP-F, and alter the association of CENP-E with the microtubules. J Biol Chem 275: 30451-30457, 2000.
9. Shih C and Weinberg RA: Isolation of transforming sequence from a human bladder carcinoma cell line. Cell 29: 161-169 (1982).
10. Lowy DR and Willumsen BM: Function and regulation of ras. Ann Rev Biochem 62: 851-891, 1993.
11. Casey PJ: Biochemistry of protein prenylation. J Lipid Res 33: 1731-1740, 1992.
12. Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ and End DW: Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol 6: 470-476, 2001.
13. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB and Cowan KH: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18: 927-941, 2000.
14. Duronio V, Welham MJ, Abraham S, Dryden P and Schrader JW: p21ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21ras GTPase-activating protein. Proc Natl Acad Sci USA 89: 1587-1591, 1992.
15. Heilmeyer LM, Serwe M, Weber C, Metzger J, Hoffmann-Posorske E and Meyer HE: Farnesylcysteine, a constituent of the a and b subunits of the rabbit skeletal muscle phosphorylase kinase: localization by conversion to S-ethylcysteine and by tandem mass spectrometry. Proc Natl Acad Sci USA 89: 9554-9558, 1992.
16. Patnik A, Eckhardt S, Itzbicka E, Hildalgo M, McCreery H, Mori M, Terada K, Tolcher A, Smith L, Britten C, Bowden C, Bol K, Ochon L, Davidson K, Hammond L, Schwartz G, Horak I, Gentner L and Rowinsky E: A phase I and pharmacokinetic (PK) study of the farnesyltransferase inhibitor R115777 in combination with gemcitabine (Gem). Proc Am Soc Clin Oncol 19: 5A, 2000.
17. Hurwitz HI, Amado R and Prager D: Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66366 plus gemcitabine in advanced cancers. Proc Am Soc Clin Oncol 19: 717, 2000.
18. Verslype C, Steenbergen WV, Humblet Y, Marse H, De Vis J, Palmer P, Seifert W, Bol C and van Cutsem E: Phase I trial of 5-FU/LV in combination with the farnesyltransferase inhibitor (FTI) R115777. Proc Am Soc Clin Oncol 20: 681, 2001.
19. Liu M, Bryant MS and Chen J: Antitumor activity of SCH66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 58: 4947-4956, 1998.
20. Moasser MM, Sepp-Lorenzino L and Kohl NE: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothiones. Proc Natl Acad Sci USA 95: 1369-1374, 1998.
21. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W and Bowden C: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61: 131-137, 2001.
22. Rak J, Mitsuhhashi Y and Bayko L: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995.
23. Khuri FR, Glisson BS, Meyers ML, Herbst RS, Thall PF, Munden RF, Bangert S, Cascino M, Blumenschein G, Pisters K and Hong WK: Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/saftety. Proc Am Soc Clin 19: 205a, 2000.
24. Karp JE and Mookerjee BP: Overcoming drug resistance: targeting more than one site. Leuk Res 1: 107-109, 2002.
25. Schwartz G, Rowinsky EK, Rha SY, Hammond LA, Smith L, Patnaik A, Hildalgo M, Berg K, Izbicka E and Tolcher AW: A phase I, pharmacokinetic, and biologic correlative study of R115777 and trastuzumab (Herceptin) in patients with advanced cancer. Proc Am Soc Clin Oncol 20: 322, 2001.
26. Bernhard EJ, Kao G and Cox AD: The farnesyl transferase inhibitor FTI-277 radiosensitizes H-ras transformed rat embryo fibroblasts. Cancer Res 56: 1727-1730, 1996.
27. Hruban RH, van Offerhaus GJ, Allison DC, Goodman SN, Kensler TW, Bose KK, Camerons JL and Bos JL: K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allee-specific oligonucleotide hybridization. Am J Pathol 143: 545-554, 1993.
28. Breivik J, Meling GI, Spurkland A, Rognum TO and Gaudernack G: K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer 69: 367-371, 1994.
29. Slebos RJC, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJLM, Wagenaar SS, Vanderschueren RG, van Zandwijk N, Moni WJ, Bos JL and Rodenhuis S: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323: 561-565, 1990.
30. Abo J, Inokuchi K, Dan K and Nomura T: p53 and-N-ras-mutations in two new leukemia cell lines established from a patient with multilineage CD7-positive leukemia. Blood 82: 2829-2836, 1993.
31. Eskens F, Awada A, Verweij J, Cutler DL, Hanauske A and Piccart M: Phase I and pharmacologic study of continuous daily oral SCH66336, a novel farnesyl transferase inhibitor, in patients with solid tumors. Proc Am Soc Clin Oncol 18: 600, 1999.
32. Britten CD, Rowinsky E and Yao SL: The farnesyl protein transferase (FPTase) inhibitor L-778123 in patients with solid cancers. Proc Am Soc Clin Oncol 18: 155A, 1999.
33. Ryan DP, Eder JP and Supko JG: Phase I clinical trial with the farnesyltransferase inhibitor BMS 214662 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 19: 720, 2000.